| Officer | Age | 2025 pay | Source |
|---|---|---|---|
|
Bill Sibold
Also a director
President and Chief Executive Officer
|
59 | $19,206,341 | |
|
William John Sibold
President and CEO
Title from the Form 4 dated Sep 9, 2026
|
Not stated | Not reported | |
|
Mardi Dier
Executive Vice President and Chief Financial Officer
|
62 | $6,085,089 | |
|
Carole Huntsman
Executive Vice President and Chief Commercial Officer
|
61 | $5,441,736 | |
|
Shannon Kelley
General Counsel
Title from the Form 4 dated Nov 6, 2026
|
51 | $5,179,352 | |
|
David Soergel
Executive Vice President and Chief Medical Officer
|
58 | $9,190,678 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 28, 2026 · updated by the 8-K of Aug 12, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Julian C. Baker
Board chair
|
59 |
2023
3 years
|
Independent | None stated | Incyte Corporation, Acadia Pharmaceuticals, Inc., Denali Therapeutics Inc. | $503,397 | |
|
Bill Sibold
CEO
|
59 |
2023
3 years
|
Not independent | None stated | None stated | Paid as CEO | |
|
Daniel J. Brennan
|
60 |
2025
1 year
|
Independent | None stated | Waters Corporation | $613,097 | |
|
Raymond Cheong, M.D., Ph.D.
|
44 |
2023
3 years
|
Independent |
Compensation Committee
Science and Technology Committee · Chair
|
vTv Therapeutics Inc. | $494,897 | |
|
James M. Daly
|
64 |
2019
7 years
|
Independent |
Audit Committee
Nominating and Governance Committee
|
Acadia Pharmaceuticals, Inc., argenx SE, Cytokinetics Inc. | $477,022 | |
|
Jacqualyn A. Fouse, Ph.D.
|
64 |
2025
1 year
|
Independent |
Audit Committee
Compensation Committee
Nominating and Governance Committee
|
Incyte, Agios | $761,744 | |
|
Richard S. Levy, M.D.
|
68 |
2016
10 years
|
Independent |
Compensation Committee · Chair
Nominating and Governance Committee
Science and Technology Committee
|
ProTara Therapeutics, Inc., Kodiak Sciences, Inc., Kiniksa Pharmaceuticals, Ltd. | $494,897 | |
|
Rebecca Taub, M.D.
|
74 |
2016
10 years
|
Not independent | None stated | BriaCell Therapeutics Corp., Inc. | Not stated | |
|
Paul A. Friedman, M.D.
|
Not stated | Not stated | Not independent |
Science and Technology Committee
|
None stated | $469,147 | |
|
John C. Reed
Joined Aug 11, 2026
|
- | - | - |
Science and Technology Committee
|
- | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Apr 28, 2026 describes a review policy but reports no transactions.
Read the policy in the proxyLoading...